Compare FICO & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FICO | RMD |
|---|---|---|
| Founded | 1956 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.7B | 36.8B |
| IPO Year | 1995 | N/A |
| Metric | FICO | RMD |
|---|---|---|
| Price | $1,247.70 | $257.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 11 |
| Target Price | ★ $1,999.46 | $293.70 |
| AVG Volume (30 Days) | 322.1K | ★ 1.3M |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 0.92% |
| EPS Growth | ★ 29.78 | N/A |
| EPS | ★ 6.61 | N/A |
| Revenue | ★ $1,032,475,000.00 | N/A |
| Revenue This Year | $26.73 | $10.64 |
| Revenue Next Year | $18.15 | $7.38 |
| P/E Ratio | $194.15 | ★ $25.61 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1,268.00 | $199.92 |
| 52 Week High | $2,217.60 | $293.81 |
| Indicator | FICO | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 25.22 | 51.32 |
| Support Level | N/A | $241.41 |
| Resistance Level | $1,585.31 | $259.24 |
| Average True Range (ATR) | 56.50 | 7.67 |
| MACD | -2.13 | -0.44 |
| Stochastic Oscillator | 8.99 | 41.42 |
Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's US-centric credit scores business accounts for most of the firm's revenue and profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.